Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria

Jerry M. Wells,Annick Mercenier

DOI: https://doi.org/10.1038/nrmicro1840

IF: 88.1

2008-05-01

Nature Reviews Microbiology

Abstract:Key PointsImportant developments in the design of recombinant lactic acid bacteria (LAB) as mucosal carriers for a range of health-beneficial compounds, such as antigens, allergens, immune modulators, antimicrobial and trefoil peptides, single-chain antibodies and a few enzymes, have taken place in the past decade. The different approaches, strategies and proof-of-concept studies that have been conducted in animal models are reviewed in this article.The rationale for the use of lactic acid bacteria as mucosal delivery vehicles and key aspects of their interaction with the host mucosal surfaces are discussed.An overview of the progress in the field of LAB-based mucosal vaccines and a discussion of protection studies that have been conducted in rodents, mainly by intranasal and intragastric immunization, are provided.The latest developments in the use of LAB as vechicles for DNA vaccination are described.Studies that deal with successful delivery of cytokines or trefoil peptides to treat experimental colitis in rodents are reviewed. Notably, the first Phase I trial has been conducted with patients that suffer from inflammatory bowel disease using safe biologically contained recombinant lactococci that secrete human interleukin-10.Efforts to induce oral tolerance and develop preventive strategies against type I allergies using LAB are highlighted.Anti-infective strategies that are based on the delivery of microbicidal peptides are discussed, with a special emphasis on the prevention of HIV-1 infection.The concluding section captures the key learning points in the field, identifies major questions that remain to be answered and highlights challenges for the future.

microbiology